6/30/26
JOHN WILEY & SONS (JW-A)
Thesis: John Wiley & Sons: the story is balanced — Open-access publishing policy changes from government funding agencies (NIH…
What Moves the Stock
- 1Open-access publishing policy changes from government funding agencies (NIH, European Commission) that pressure subscription revenue models
- 2Higher education enrollment trends and university budget allocations for library subscriptions and courseware
- 3Digital courseware adoption rates and market share gains/losses versus Pearson, Cengage, and McGraw-Hill in key course categories
- 4Portfolio rationalization progress and margin expansion from exiting lower-margin print assets
- 5Research output volume from universities and corporate R&D departments driving article submissions and publication fees
- 6Research Publishing (estimated 50-55%): Subscription-based academic journals and databases serving institutional libraries and researchers
- 7Academic & Professional Learning (estimated 30-35%): Digital courseware, textbooks, and online learning platforms for higher education
- 8Professional Development (estimated 10-15%): Certification prep, continuing education, and workforce training content
My Notes
- value - The stock trades at 1.3x sales and 7.1x EV/EBITDA, below historical publishing multiples…
- Rising interest rates negatively impact Wiley through two channels: (1) higher debt service costs on the 1.20x debt/equity ratio…
- Watch on earnings: Federal student loan interest rates and Pell Grant funding levels affecting higher education affordability and enrollment, University endowment performance and state higher education appropriations driving library budget growth, Research funding levels from NIH, NSF, and European research councils determining article submission volumes.
One Sentence Summary:
John Wiley & Sons: the story is balanced — open-access publishing policy changes from government funding agencies (nih, european commission) that pressure subscription revenue models.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.